Carlotta01

{ "short_title": "Carlotta01", "data_mode": "900", "data_mode_number": "000002302", "official_title": "A Phase I trial to establish the safety and maximum \r\ntolerated dose of high-affinity autologous BCMA-\r\ntargeting CAR T-cells in patients with relapsed and \r\nrefractory B-cell malignancies \r\nCARLOTTA01 ", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "not_applicable", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": null, "eudract_number": "2022-502831-20", "general_contact_email": null, "general_contact_phone": null, "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Eine Phase-I-Studie zur Ermittlung der Sicherheit und der maximal vertr\u00e4glichen Dosis \r\nvon autologen, hochaffinen, auf BCMA gerichteten CAR-T-Zellen zur Behandlung von \r\nPatienten mit rezidivierten/refrakt\u00e4ren malignen B-Zellerkrankungen \r\nCARLOTTA01", "description_laie_en": null, "description_expert_de": null, "description_expert_en": "A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-\r\ntargeting CAR-T cells in patients with relapsed and refractory B-cell malignancies", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 4, "sub_cat_id": 26 }